NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SXTC
China SXT Pharmaceuticals, Inc.
There isn't enough reported data to score SXTC yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SXTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
SXTC's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SXTC PE Valuation
SXTC has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SXTC Forward outlook
There aren't enough analyst estimates for SXTC to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SXTC in the latest year-over-year earnings comparison.
SXTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2019 | $1,440,000,000.00 | +6592401% |
SXTC has swung to a loss: it lost $258,864,000.00 per share over the past year, after a profit the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SXTC in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SXTC on profitability, with a higher operating margin.
SXTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $511.5K | -44% |
| Q3 2025 | $626.6K | -24% |
| Q1 2025 | $911.4K | -7.8% |
| Q3 2024 | $829.5K | -12% |
| Q1 2024 | $988.9K | +30% |
| Q3 2023 | $939.6K | -22% |
| Q1 2023 | $763.4K | -52% |
| Q3 2022 | $1.2M | +18% |
SXTC's revenue has slid since its 2019 peak: $511,482 last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -153% | -844 points |
| Q3 2025 | -1012% | -17 points |
| Q1 2025 | -224% | +360 points |
| Q3 2024 | -77% | +18 points |
| Q1 2024 | 691% | +837 points |
| Q3 2023 | -995% | -714 points |
| Q1 2023 | -584% | -217 points |
| Q3 2022 | -95% | -125 points |
SXTC's operating margin was −153% last quarter, down 844 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
SXTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2022 | -$569.2K | -$235.8K |
| Q1 2022 | $540.8K | +$1.6M |
| Q3 2021 | -$333.5K | +$5K |
| Q1 2021 | -$1.1M | -136% |
| Q3 2020 | -$338.4K | +$1.8M |
| Q1 2020 | $3M | +$3.2M |
| Q1 2019 | -$296.6K | -126% |
| Q1 2018 | $1.2M | +2543% |
SXTC has the edge over NVO in the latest year-over-year cash flow comparison.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SXTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -85% | -88 shares |
| Quarter | Spent |
|---|---|
| Q1 2018 | — |
| Q4 2017 | — |
| Q3 2017 | — |
| Q2 2017 | — |
| Q1 2017 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SXTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -2.8x | Net Cash |
| Q3 2020 | -24.2x | Net Cash |
| Q1 2019 | -4.7x | Net Cash |
| Q1 2018 | -0.1x | Net Cash |
| Q4 2017 | 0.1x | Very low |
SXTC has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SXTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 0.0 | Oversold |
SXTC's weekly RSI is 26 (oversold) and its Stochastic is 0 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SXTC PE vs Healthcare Sector
| Metric | SXTC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SXTC has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over SXTC on trend strength, trading above more of its moving averages.
SXTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.5 | 96% below |
| 20 week MA | $3,168.2 | 100% below |
| 50 week MA | $201,104.1 | 100% below |
| 100 week MA | $1,416,712.0 | 100% below |
| 200 week MA | $16,515,528.3 | 100% below |
SXTC is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SXTC on returns for 2026, with the stronger performance.
SXTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14,687,808,000.0 | $6,504,960,000.0 | -56% |
| 2021 | $6,504,960,000.0 | $2,753,856,000.0 | -58% |
| 2022 | $2,753,856,000.0 | $124,800,000.0 | -95% |
| 2023 | $124,800,000.0 | $38,112,000.0 | -69% |
| 2024 | $38,112,000.0 | $4,012,800.0 | -89% |
| 2025 | $4,012,800.0 | $1,812,000.0 | -55% |
| 2026 YTD | $1,812,000.0 | $2.73 | -100% |
SXTC has finished every year since 2020 lower, and it's down 100% so far in 2026.